Does ecopipam, a selective dopamine D1 receptor antagonist, maintain tic improvement and remain well tolerated for up to 24 weeks in patients with Tourette syndrome?
Does prasinezumab delay motor progression in early-stage Parkinson's disease patients receiving standard-of-care symptomatic medications (levodopa or MAO-B inhibitors)?
PADOVA
PrAsinezumab in early-stage Parkinson's Disease in levodopa (L-DOPA)- or MAO-Bi-treated patients - efficacy and safety eVAluation
Parkinsonism and Related Disorders · 2025
Bottom Line: PADOVA is a Phase 2b trial designed to confirm the efficacy signal observed in PASADENA by testing prasinezumab in a broader, more representative early-stage PD population on stable symptomatic therapy. The study successfully enrolled 586 participants and reached primary completion in September 2024. Results pending.